Basking Ridge-based Regado Biosciences Inc. announced Friday the pricing of its previously announced public offering of 10 million shares of its common stock.
According to the announcement, the company is offering a price of $6.00 per share to the public. Regado expects to make approximately $60 million from this offering and plans to use the proceeds to fund further clinical development of its lead product, for working capital and other general corporate purposes.
The offering is expected to close on or about April 16, 2014. The company has granted underwriters 30-days top purchase up to 1.5 million additional shares of the stock.
Jefferies LLC, Deutsche Bank Securities and Cowen and Company LLC, will act as joint bookrunning managers for the offering.